From the above results, it can be concluded that iRGD and Trast functionalization leads to better cytotoxic effects on SK-BR-3 and MDA-MB-231 cells and may be a promising candidate for HER2-positive metastatic breast cancer treatment. Here, ERBB2 is linked to breast carcinoma.